Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 66Advanced Solid Tumor 56Solid Tumor 42Solid Tumors 40Mesothelioma 38Mesothelioma, Malignant 34Hematopoietic and Lymphatic System Neoplasm 23Solid Tumor, Adult 14Ovarian Neoplasms 13Malignant Solid Neoplasm 13Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 11Melanoma 11Sarcoma 10Retinoblastoma 9Colorectal Neoplasms 9Stomach Neoplasms 8Lung Neoplasms 8Solid Tumours 7Small Cell Lung Carcinoma 7Advanced Malignant Solid Neoplasm 7Kidney Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 6Advanced/Metastatic Solid Tumors 6Advanced or Metastatic Solid Tumors 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
MSI-H × Other solid neoplasm × 90 days × Clear all
NCT05890742 2026-05-28

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Active not recruiting
453 enrolled
Other solid neoplasm

MSI-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡